<DOC>
	<DOCNO>NCT00505700</DOCNO>
	<brief_summary>The primary objective study establish maximally tolerate dose VELCADE administer idarubicin cytarabine patient AML . The secondary objective study assessment efficacy , safety , pharmacokinetics Velcade combine Cytarabine idarubicin . Various molecular marker associate response Velcade , cytarabine , idarubicin explore utilizing microarray analysis . The study endpoint maximum tolerate dose response treatment .</brief_summary>
	<brief_title>VELCADE Combination With Idarubicin Cytosine Arabinoside Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Patients must 18 year old . Unequivocal histologic diagnosis AML ( &gt; 20 % blast blood and/or bone marrow base WHO and/or FAB classification describe Appendix 9.3 ) , exclude M3 ( acute promyelocytic leukemia ) . For patient le 60 , disease must previously achieve CR relapse ( &gt; 20 % blast blood and/or bone marrow base WHO and/or FAB classification describe Appendix 9.3 ) , exclude M3 ( acute promyelocytic leukemia ) . ) . These patient must period remission &gt; 3 month ( begin time ANC &gt; 1,500/ul , platelet &gt; 100,000/ul &lt; 5 % marrow blast present ) . Patients 60 year age old may relapse disease may previously untreated AML ( &gt; 20 % blast blood and/or bone marrow base WHO and/or FAB classification describe Appendix 9.3 ) , exclude M3 ( acute promyelocytic leukemia ) . Patients may prior myelodysplasia . Patients may prior treatment myelodysplasia . Patients may prior chemotherapy another malignancy antecedent hematologic disorder myelodysplasia . Patients must ECOG performance status 03 . Patients must follow pretreatment laboratory value within 21 day enrollment : total bilirubin &lt; = 1.5 X upper limit normal ( ULN ) , ALT AST &lt; = 2.5 X ULN , creatinine &lt; = 2.0 mg/dl . Male patient need use appropriate method barrier contraception study . Female patient must postmenopausal , surgically sterilize , willing use acceptable method birth control ( i.e . hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Patients must give voluntary write informed consent performance studyrelated procedure part normal medical care . If less 60 year old , patient receive chemotherapy within last three month ( 90 day ) . Patients untreated AML &lt; 60 year old . Other active malignancy ( exception basal squamous cell skin cancer ) time study entry . Patient hypersensitivity boron mannitol Severe pulmonary cardiac disease . History congestive heart failure ejection fraction &lt; 40 % . Patient myocardial infarction within 6 month enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Patients M3 AML ( acute promyelocytic leukemia ) FAB WHO describe 9.3 . Patients HIV infection . Patients know active hepatitis B C. Patients known central nervous system leukemia . A lumbar puncture require unless CNS involvement clinically suspect . Patients pregnant breast feed . Patients major surgery within 4 week prior trial enrollment . Patients Â³ Grade 2 peripheral neuropathy within 21 day enrollment . Patients uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . If condition become control , patient may become eligible . Patients serious medical psychiatric illness could , investigator 's opinion , potentially interfere completion treatment accord protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>acute myeloid leukemia</keyword>
</DOC>